DAVID MAHONEY - 02 Jun 2021 Form 4 Insider Report for Adamas Pharmaceuticals Inc (ADMS)

Role
Director
Signature
/s/ Christopher B. Prentiss, Attorney-in-fact
Issuer symbol
ADMS
Transactions as of
02 Jun 2021
Transactions value $
$0
Form type
4
Filing time
04 Jun 2021, 16:15:41 UTC
Previous filing
28 May 2021
Next filing
24 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMS Common Stock Award $0 +5K +4.54% $0.00 115K 02 Jun 2021 Direct F1
holding ADMS Common Stock 2.63K 02 Jun 2021 David L. Mahoney & Winnifred C. Ellis 1998 Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMS Stock Option (Right to Buy) Award $0 +10K $0.00 10K 02 Jun 2021 Common Stock 10K $5.21 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.
F2 The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.